Population Health Alliance is proud of its partnership with Bayer Global, and pleased they came on board as our first Corporate Partner.
PHA as the industry’s only multi-stakeholder professional and trade association solely focused on population health management, and Bayer Pharmaceuticals, a multi-national pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world know the teaming up in a special partnership is a perfect fit. Bayer is dedicated to helping PHA to achieve its mission to improve health outcomes, optimize the consumer and provider experience, and drive affordability.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.
We are pleased to showcase the fine work that Bayer does in this arena and are grateful that our members can use them as an important resource.
CKD Clinical Guidelines and Research Trials
Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.
Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes (T2D) that affects approximately 40% of patients. T2D disproportionately affects Black and Hispanic Americans. Despite its frequency, most patients are unaware of CKD and the increased risk of cardiovascular events associated with it. Early detection of CKD may improve patient outcomes and help prevent cardiovascular-related events and deaths. Diabetes is estimated to affect over 10% of adults in the U.S., primarily those over the age of 45, with type 2 diabetes (T2D) accounting for 90-95% of cases. In patients with T2D, up to 40% develop chronic kidney disease (CKD), which damages the kidney and reduces its ability to filter waste. CKD also greatly increases the risk of cardiovascular complications, with the risk of cardiovascular death increasing as CKD progresses. In fact, patients with stage 3 CKD are over 10 times more likely to die than progress to kidney failure. Damage from CKD cannot be reversed, but with the advent of new kidney-protecting treatments, early detection of CKD allows patients and their health care providers to create a plan that may slow CKD progression and reduce cardiovascular risk.
Unfortunately, fewer than a quarter of at-risk patients are tested for CKD. Because many patients are unaware of the disease risk—9 out of 10 patients with CKD do not know they have it—they may not ask their doctors to be screened. Without screening, CKD often progresses unnoticed because symptoms do not appear until severe kidney damage occurs and a patient has an imminent need for treatment.
Bayer Support Resources
In addition to its work with PHA, Bayer works with other leading medical and clincal organizations on offering resouces and sharing research on one of its major priorities — Chronic Kidney Disease (CKD) to improve the quality of care of this common, but under-recognized condition. Fifthteen percent (15%) of US adults are estimated to have chronic kidney disease — about 37 million people. Please click on the following, to learn more:
The National Committee for Quality Assurance (NCQA) developed a Kidney Health Tookit with financial support from Bayer Healthcare Pharmaceutials, Inc. Visti the NCQA website to access this information.
National Kidney Foundation (NFK) – Bayer, along with NKF and award-winning actress, Debbie Allen launched the “Are You the 33%?” a national public awareness campaign in February 2021 to focus attention on the increased risk of developing chronic kidney disease,.
American Society of Nephrology – ASN leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care. Bayer is a platnium-level partner.